Haemonetics (HAE) Gross Profit (2016 - 2025)
Haemonetics has reported Gross Profit over the past 17 years, most recently at $202.4 million for Q4 2025.
- For Q4 2025, Gross Profit rose 4.57% year-over-year to $202.4 million; the TTM value through Dec 2025 reached $782.4 million, up 6.92%, while the annual FY2025 figure was $749.0 million, 8.3% up from the prior year.
- Gross Profit for Q4 2025 was $202.4 million at Haemonetics, up from $194.7 million in the prior quarter.
- Over five years, Gross Profit peaked at $202.4 million in Q4 2025 and troughed at $81.8 million in Q2 2021.
- A 5-year average of $161.6 million and a median of $168.9 million in 2023 define the central range for Gross Profit.
- Biggest five-year swings in Gross Profit: dropped 27.96% in 2021 and later soared 66.63% in 2022.
- Year by year, Gross Profit stood at $122.5 million in 2021, then increased by 29.51% to $158.7 million in 2022, then increased by 12.07% to $177.9 million in 2023, then increased by 8.82% to $193.5 million in 2024, then grew by 4.57% to $202.4 million in 2025.
- Business Quant data shows Gross Profit for HAE at $202.4 million in Q4 2025, $194.7 million in Q3 2025, and $192.2 million in Q2 2025.